SCHEMBL3499442

SCHEMBL3499442

Cc1cc2nc(C(=O)O)cn2c(C)c1-c1ccc(Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA2 P47869 1/20 0.46
GABRB2 P47870 1/20 0.46
SMN1; SMN2 Q16637 6/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
MAPT P10636 1/20 0.42
AHR P35869 1/20 0.42
PPP1CA P62136 1/20 0.41
KDM4E B2RXH2 2/20 0.40
LMNA P02545 2/20 0.40
TP53 P04637 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
POLB P06746 1/20 0.40
RPA1 P27694 1/20 0.39
MAP4K4 O95819 1/20 0.39
KMO O15229 1/20 0.39
DHODH Q02127 4/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
MCL1 Q07820 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3498691 0.84 GABRA2 (0.55) GABRA2GABRB2MAPTKDM4EPOLB
SCHEMBL3498219 0.80 SMN1; SMN2 (0.47) GABRA2GABRB2SMN1; SMN2NPC1RAB9A
SCHEMBL3498341 0.75 GABRA2 (0.47) GABRA2GABRB2SMN1; SMN2NPC1RAB9A
SCHEMBL3497394 0.70 PPP1CA (0.48) GABRA2GABRB2SMN1; SMN2PPP1CARPA1
SCHEMBL3499356 0.68 RXFP1 (0.58) GABRA2GABRB2SMN1; SMN2NPC1RAB9A
SCHEMBL3498537 0.68 EGLN1 (0.67) GABRA2GABRB2NPC1RAB9AKDM4E
SCHEMBL3498830 0.68 PTGS1 (0.51) GABRA2GABRB2SMN1; SMN2NPC1RAB9A
SCHEMBL3367405 0.67 PTGS1 (0.40) GABRA2GABRB2SMN1; SMN2NPC1RAB9A
SCHEMBL11345938 0.67 GABRA2 (0.43) GABRA2GABRB2KDM4EHPGDHSD17B10
SCHEMBL3499262 0.67 GABRA2 (0.46) GABRA2GABRB2SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function GPR34, GPR4, GPR6 GABRA2 317/4885GABRB2 169/4885SMN1; SMN2 4779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.